Jodie Thomas, APRN
Nurse Practitioner · Elizabethtown, KYNPI 1891269031
Payments from drug & device makers
Across 340 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$674
- Lilly USA, LLC$667
- BETA Bionics, Inc.$455
- AbbVie$409
- Sanofi-aventis U.S. LLC$401
- plus $4K from 32 others
What the payments were for
- Travel & lodging$1,05813%
- Food & beverage$7,19687%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 29 | $2,050 |
| Novo Nordisk | 26 | $674 |
| Lilly USA, LLC | 36 | $667 |
| BETA Bionics, Inc. | 15 | $455 |
| AbbVie | 32 | $409 |
| Sanofi-aventis U.S. LLC | 11 | $401 |
| Averitas Pharma Inc. | 14 | $334 |
| Insulet Corporation | 19 | $310 |
| Corcept Therapeutics | 13 | $286 |
| Bayer | 14 | $233 |
| AstraZeneca(2 entities) | 7 | $231 |
| Tandem Diabetes Care, Inc. | 13 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $198 |
| Boehringer Ingelheim | 12 | $197 |
| Amgen | 10 | $163 |
| Abbott | 11 | $149 |
| GSK | 9 | $145 |
| Cequr Corporation | 2 | $128 |
| Dexcom, Inc. | 2 | $123 |
| Novartis | 7 | $114 |
| Mannkind Corporation | 5 | $110 |
| Biohaven Pharmaceuticals, Inc. | 5 | $82 |
| Xeris Pharmaceuticals, Inc. | 3 | $70 |
| Astellas Pharma US Inc | 4 | $68 |
| Pfizer | 4 | $66 |
| Amphastar Pharmaceuticals, Inc. | 4 | $57 |
| Merck | 3 | $50 |
| Nevro Corp. | 2 | $42 |
| Sequel Med Tech, LLC | 2 | $42 |
| Johnson & Johnson | 2 | $40 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Globus Medical | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Organogenesis Inc. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,419
- iLet Bionic Pancreas$323
- TZIELD$126
- FARXIGA$125
- Ozempic$125
- Wegovy$124
- iLet Insulin Infusion Kit Inset$108
- iLet Insulin Infusion Kit Contact Detach$108
- LYUMJEV$107
- DEXCOM G7 GSS (161)$106
How this compares
$8,254 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 184 | $248,160 |
| JardianceEmpagliflozin | 148 | $180,887 |
| MounjaroTirzepatide | 114 | $156,149 |
| FarxigaDapagliflozin Propanediol | 69 | $78,025 |
| TrulicityDulaglutide | 44 | $77,556 |
| JanuviaSitagliptin Phosphate | 58 | $64,862 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $56,227 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $56,130 |
| RybelsusSemaglutide | 35 | $48,278 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 63 | $42,172 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $39,945 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 181 | $28,032 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $27,798 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $24,152 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 22 | $23,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $674 | $301,345238 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $667 | $238,478193 claims |
| Boehringer IngelheimJardiance | $197 | $180,887148 claims |
| MerckJanuvia, Janumet | $50 | $89,01380 claims |
| AstraZenecaFarxiga | $231 | $78,02569 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $401 | $27,79827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Elizabethtown
- Jennifer WhitsellElizabethtown$13K
- Tiffany RichardsonElizabethtown$10K
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.